Abstracts tagged "morbidity and mortality"

Abstract Number: 698 • 2012 ACR/ARHP Annual Meeting
External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients
Robyn T. Domsic¹, Svetlana Nihtyanova², Stephen R. Wisniewski³, Michael J. Fine⁴, C. Kent Kwoh⁵, Christopher P. Denton⁶ and Thomas A. Medsger Jr.⁷, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology, Royal Free Hospital, Medical School, London, England, ³Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴General Medicine, University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, ⁵School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁷Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA
Background/Purpose: The ability to risk stratify patients for short term mortality is important in SSc patient care and clinical trial design; but there is…
Abstract Number: 290 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes in Neonatal Lupus
Amit Saxena¹, Peter M. Izmirly², Deborah Friedman³ and Jill P. Buyon⁴, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Division of Pediatric Cardiology, New York Medical College, Valhalla, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Several studies have evaluated mortality and short-term morbidity in neonatal lupus (NL), however there have been no substantive descriptions of the long term cardiac,…
Abstract Number: 291 • 2012 ACR/ARHP Annual Meeting
Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies
Adam M. Huber¹, Gulnara Mamyrova², Julia A. Lee³, Peter A. Lachenbruch⁴, Ira N. Targoff⁵, Frederick W. Miller⁴, Lisa G. Rider⁴ and Childhood Myositis Heterogeneity Study Group⁶, ¹Dalhousie University, Halifax, NS, Canada, ²Rheumatology, George Washington University, Washington, DC, ³Environmental Autoimmunity Grp, NIEHS, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are potentially life-threatening systemic autoimmune diseases but little in known regarding factors associated with mortality. Methods: Patients enrolled in…
Abstract Number: 217 • 2012 ACR/ARHP Annual Meeting
Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis
Christine McBurney¹, Rohit Aggarwal², Kevin Gibson³, Kathleen Lindell⁴, Carl Fuhrman⁵, Diane Koontz⁶, Frank Schneider⁷, Naftali Kaminski⁴ and Chester V. Oddis⁸, ¹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴University of Pittsburgh Dorothy P. & Richard P. Simmons Center for Lung Disease, Pittsburgh, PA, ⁵Radiology, Division of Thoracic Imaging, University of Pittsburgh, Pittsburgh, PA, ⁶Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Anatomic Pathology Department, Pittsburgh, PA, ⁸Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Usual interstitial pneumonia associated with idiopathic pulmonary fibrosis (IPF-UIP) has a poor prognosis with a median survival of 3 years. It is unknown whether…
Abstract Number: 2559 • 2012 ACR/ARHP Annual Meeting
Mortality in Patients with Psoriatic Arthritis Compared to Patients with Rheumatoid Arthritis, Psoriasis Alone, and the General Population
Alexis Ogdie¹, Kevin Haynes², Andrea Troxel², Thorvardur Love³, Hyon K. Choi⁴ and Joel Gelfand⁵, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ³Landspitali University Hospital, Reykjavik, Iceland, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵University of Pennsylvania., Philadelphia, PA
Background/Purpose: Conflicting reports of the mortality risk among patients with psoriatic arthritis (PsA) exist in the literature, however excess mortality has been presumed given the…
Abstract Number: 2044 • 2012 ACR/ARHP Annual Meeting
Trying to Improve Care: A Review of the Morbidity and Mortality Conference in the Division of Rheumotology
Michelle Batthish¹, Shirley Tse², Brian M. Feldman³, G. Ross Baker⁴ and Ronald Laxer⁵, ¹Pediatric Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Institute of Health Policy, Management and Evaluation, The University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: The morbidity and mortality conference (M&MC) is one of academic medicine’s most visible fora for discussion of adverse events and errors; however it is…
Abstract Number: 1665 • 2012 ACR/ARHP Annual Meeting
Associations of Race and Ethnicity with Overall Mortality and Cardiovascular Events Among Patients with End-Stage Renal Disease Due to Lupus Nephritis
Jose A. Gomez-Puerta¹, Sushrut Waikar², Graciela S. Alarcon³, Jun Liu⁴, Daniel H. Solomon⁵, Wolfgang C. Winkelmayer⁶ and Karen H. Costenbader⁷, ¹Section of Clinical Sciences, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ²Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁶Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with SLE and lupus nephritis (LN) are at elevated risks of cardiovascular disease. Past studies have suggested that African American patients with SLE…
Abstract Number: 1407 • 2012 ACR/ARHP Annual Meeting
The Effect of the Antiphospholipid Syndrome (APS) On Survival in Chinese Patients with SLE: A Prospective Study of 679 Patients
Chi Chiu Mok, Ling Yin Ho, Ka Lung Yu and Chi Hung To, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the effect of the antiphospholipid syndrome (APS) on survival in Chinese patients with SLE Methods: A cohort of 679 southern Chinese patients…
Abstract Number: 1410 • 2012 ACR/ARHP Annual Meeting
Relationship Between Individual Organ Damage and Mortality of Systemic Lupus Erythematosus (SLE): A Prospective Cohort Study of 679 Patients
Chi Chiu Mok, Ling Yin Ho and Ka Lung Yu, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the relationship between damage in different organ systems and mortality in patients with SLE. Methods: 679 patients who fulfilled at least 4…
Abstract Number: 936 • 2012 ACR/ARHP Annual Meeting
Autoimmune Diseases: Declining Mortality Between 1999 and 2008 However Continuing to be a Leading Cause of Death in Children-A 10-Year Retrospective Review
Eric Y. Yen¹ and Deborah K. McCurdy², ¹Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ²Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA
Background/Purpose: Autoimmune diseases are chronic illnesses that cause significant and chronic disability in children and may lead to death. Using mortality data from 1995, Walsh…
Abstract Number: 724 • 2012 ACR/ARHP Annual Meeting
Survival, Hospitalization or Need for Combination Therapy At One Year in Patients with Scleroderma-Associated Pulmonary Arterial Hypertension
Robyn T. Domsic¹, Lorinda Chung², Jessica K. Gordon³, Yona Cloonan⁴, Virginia D. Steen⁵ and PHAROS Investigators⁶, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁶Washington, DC, DC
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). Although survival has improved with PAH-specific medications in…
Abstract Number: 728 • 2012 ACR/ARHP Annual Meeting
Does the Use of Angiotensin Converting Enzyme Inhibitors Prior to Scleroderma Renal Crisis Affect Prognosis ? – Results of the International Scleroderma Renal Crisis Survey
Marie Hudson¹, Murray Baron², Solene Tatibouet¹, Daniel Furst³, Dinesh Khanna⁴ and International Scleroderma Renal Crisis Study Investigaots⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Montreal
Background/Purpose: Scleroderma renal crisis (SRC) is an infrequent but life-threatening complication of systemic sclerosis (SSc). The outcome of SRC has improved considerably since the advent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].